Dr. Altman's research is focused on increasing understanding of the role of aberrant signal transduction pathways in the development of myeloid neoplasms; defining molecular targets for the treatment of leukemias; and generating clinical trials based on such research work. With extensive experience in translational work in this area, she actively participated in work to define the roles mTOR and Mnk pathways in the generation of anti-leukemic responses in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals
AbbVie
Genentech
Amgen

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811